The present invention provides a monomeric insulin analog formulation stabilized
against aggregation in which the buffering agent is either TRIS or arginine. The
stable formulations of the present invention are useful for treating diabetes,
and are particularly advantageous in treatment regimes requiring lengthy chemical
and physical stability, such as, in continuous infusion systems.
